Tert-butyl 2-[(2R)-4-[1-(6-cyanopyridazin-4-yl)-4-fluoropyrazol-3-yl]-3-oxomorpholin-2-yl]-2-hydroxypropanoate
C19H21FN6O5 — CID 90328771
Data last refreshed: (MolForge compound catalog, from PubChem)
About Tert-butyl 2-[(2R)-4-[1-(6-cyanopyridazin-4-yl)-4-fluoropyrazol-3-yl]-3-oxomorpholin-2-yl]-2-hydroxypropanoate
Tert-butyl 2-[(2R)-4-[1-(6-cyanopyridazin-4-yl)-4-fluoropyrazol-3-yl]-3-oxomorpholin-2-yl]-2-hydroxypropanoate (PubChem CID 90328771) has the molecular formula C19H21FN6O5 and a molecular weight of 432.41 g/mol. Its IUPAC name is tert-butyl 2-[(2R)-4-[1-(6-cyanopyridazin-4-yl)-4-fluoropyrazol-3-yl]-3-oxomorpholin-2-yl]-2-hydroxypropanoate.
Molecular Properties
| Compound Name | Tert-butyl 2-[(2R)-4-[1-(6-cyanopyridazin-4-yl)-4-fluoropyrazol-3-yl]-3-oxomorpholin-2-yl]-2-hydroxypropanoate |
|---|---|
| PubChem CID | 90328771 |
| Molecular Formula | C19H21FN6O5 |
| Molecular Weight | 432.41 g/mol |
| Exact Mass | 432.16 |
| IUPAC Name | tert-butyl 2-[(2R)-4-[1-(6-cyanopyridazin-4-yl)-4-fluoropyrazol-3-yl]-3-oxomorpholin-2-yl]-2-hydroxypropanoate |
| SMILES | CC(C)(C)OC(=O)C(C)(O)[C@H]1OCCN(c2nn(-c3cnnc(C#N)c3)cc2F)C1=O |
| InChI | InChI=1S/C19H21FN6O5/c1-18(2,3)31-17(28)19(4,29)14-16(27)25(5-6-30-14)15-13(20)10-26(24-15)12-7-11(8-21)23-22-9-12/h7,9-10,14,29H,5-6H2,1-4H3/t14-,19?/m0/s1 |
| InChIKey | QHEGVIHJQFSEEC-KTQQKIMGSA-N |
| XLogP | 0.50 |
| TPSA | 143.46 Ų |
| H-Bond Donors | 1 |
| H-Bond Acceptors | 10 |
| Rotatable Bonds | 4 |
| Heavy Atoms | 31 |
| Complexity | — |
Lipinski Rule of Five
Passes Rule of Five
| Rule | Value |
|---|---|
| MW ≤ 500 | 432.41 |
| LogP ≤ 5 | 0.50 |
| H-Bond Donors ≤ 5 | 1 |
| H-Bond Acceptors ≤ 10 | 10 |
Frequently Asked Questions
Browse: Molecules A–Z · all molecules A–Z · drugs A–Z · protein targets A–Z.
Sources
- PubChem CID 90328771 — identifiers, structure, computed properties (public domain)
How this page is built: methodology · editorial policy & corrections.
For research and educational use only — not medical advice. This page is compiled automatically from public databases. It is not written or reviewed by a clinician. Do not start, stop or change any treatment based on it; consult a qualified healthcare professional. Spotted an error? See our corrections policy or email hello@molforge.ai.